Aviragen Therapeutics, Inc.

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

College De France

Quantum Genomics

Anaconda Pharma

Vaxart, Inc.

Delphine Compere

Marta Blumenfeld

Jean-Michel Gauthier

Fabrice Balavoine

Catherine Llorens-Cortes

Yannick Marc

Marco A Ciufolini

Patricia Francon

Michel Hutin

Mathilde Keck

Solène E Boitard

Solene E Boitard

The present invention relates to compounds, to compositions comprising the same, to methods for preparing the compounds, and the use of these compounds in therapy. In particular, the present invention relates to a compound that is useful in the treatment and prevention of primary and secondary arterial hypertension, ictus, myocardial ischaemia, cardiac and renal insufficiency, myocardial infarction, peripheral vascular disease, diabetic proteinuria, Syndrome X and glaucoma.

Compounds and compositions comprising the same for treating hypertension or heart failure

The present invention relates to a novel compound, to a composition comprising the same, to methods for preparing the compound, and the use of this compound in therapy. In particular, the present invention relates to a compound that is useful in the treatment and prevention of primary and secondary arterial hypertension, ictus, myocardial ischaemia, cardiac and renal insufficiency, myocardial infarction, peripheral vascular disease, diabetic proteinuria, Syndrome X and glaucoma.

Aminopeptidase A inhibitors and pharmaceutical compositions comprising the same

The present disclosure is directed to antiviral compounds directed against the papilloma virus, to pharmaceutical compositions containing them, to their preparation method and synthesis intermediates, as well as to their use for treating or preventing an infection by the papilloma virus. The present method thus provides an efficient way of treating patients that have lesions associated with an infection by the papilloma virus.

Piperidine derivatives as human papilloma virus inhibitors

The invention relates to a method for producing a hydrazine of general formula (I) and the pharmaceutically acceptable salts thereof from an amine of formula (II), characterised in that said method uses a urea of formula (III) as a synthesis intermediate. 

Method for the synthesis of a hydrazine that can be used in the treatment of the papilloma virus

The invention relates to a pharmaceutical composition including a compound of general formula (I) combined with a solvent and a viscosity-enhancing agent, as well as to the use thereof as a drug, in particular for treating and preventing infection with the papillomavirus, and to the method for preparing same. 

Pharmaceutical composition of a papillomavirus inhibitor

HPV inhibitors with formula (I) where Grepresents a hydrocarbonated bond or chain possibly substituted by one or two alkyl groups, Grepresents a group (see formula Ia+Ib) or R represents a hydrogen, an alkyl, halogenoalkyl, or a prodrug radical such as carbamate, acetyl or dialkylaminomethy, G represents a bond or a hydrocarbonated chain possibly substituted by one or two alkyls, W represents an oxygen or sulphur, Rand Reach represent a group chosen from among hydrogen, halogen, hydroxyl, thio, alkoxy, halogenoalkoxy, alkylthis, halogenoalkylthio, amino, monoalkylamino, dialkylamino, cycloalkyl, alkyl or halogenoalkyl, R3 represents an acid or a prodrug radical of the acid function or a bioisotere of the acid function, A represents an aryl, cycloalkyl, cycloalkenyl or a heterocycle with 6 chains, each possibly substituted, and pharmaceutically acceptable salts.

HPV inhibitors of formula (I) in which Gis &#x2014;NHCO(CH)n-, where n is an integer between 1 and 4, R3 is &#x2014;CW(CH)&#x2014;NR4R5 or &#x2014;CW(CH)CHor &#x2014;CN, where W is O, S or NH and m is an integer between 0 and 5, or R3 is one of the following groups: and A is an optionally substituted aryl group and B is an aryl group, preferably a phenyl which is substituted. 

Human papilloma virus inhibitors and pharmaceutical compositions containing same

HPV inhibitors with formula (I) where Grepresents a hydrocarbonated bond or chain possibly substituted by one or two alkyl groups, Grepresents a group (see formula Ia+Ib) or R represents a hydrogen, an alkyl, halogenoalkyl, or a prodrug radical such as carbamate, acetyl or dialkylaminomethyl, G represents a bond or a hydrocarbonated chain possibly substituted by one or two alkyls, W represents an oxygen or sulphur, Rand Reach represent a group chosen from among hydrogen, halogen, hydroxyl, thio, alkoxy, halogenoalkoxy, alkylthio, halogenoalkylthio, amino, monoalkylamino, dialkylamino, cycloalkyl, alkyl or halogenoalkyl, Rrepresents an acid or a prodrug radical of the acid function or a bioisostere of the acid function, A represents an aryl, cycloalkyl, cycloalkenyl or a heterocycle, each possibly substituted, and B represents an aryl or a heterocycle with 6 chains, each possibly substituted, and pharmaceutically acceptable salts. 

Growing community of inventors

Sceaux, France

Delphine Compere